Back to "Sitagliptin increased endogenous GLP-1 a..."

Strong Support

mechanistic

History

In people with obesity and prediabetes, a drug called sitagliptin raises levels of certain gut hormones but does not improve how the body responds to insulin or lower fasting blood sugar. This...

Pro

Against

Mechanism

Synthesis from 1 study

How it works

A lab-made drug sticks to GLP-1 receptors longer and harder than the body’s own hormones, turning on specific signals that help the liver and muscles use sugar better and stop the liver from making extra sugar. Just increasing the body’s natural hormones doesn’t do this — the drug has to be...

Most probable mechanism

In Simple Terms

A synthetic drug binds tightly to GLP-1 receptors in the liver, muscle, and pancreas, turning on specific cellular signals that make the body use insulin more effectively and stop the liver from making too much sugar. This happens quickly, even before weight loss, and doesn't rely on the body's own hormones. In contrast, boosting the body's natural hormones doesn't trigger the same signals or effects.

Causal chain

A synthetic GLP-1 receptor agonist binds with high affinity and prolonged duration to GLP-1 receptors on hepatocytes, skeletal muscle cells, and pancreatic alpha cells.

Verified by multiple studies

which leads to

This binding activates biased intracellular signaling pathways, including enhanced pERK1/2 activation, that differ from those triggered by endogenous GLP-1 or GIP.

Verified by multiple studies

which leads to

In the liver and muscle, this signaling improves insulin receptor substrate phosphorylation and glucose transporter translocation, increasing glucose uptake and reducing insulin resistance.

Verified by multiple studies

which leads to

In pancreatic alpha cells, direct receptor activation and enhanced paracrine signaling from insulin and somatostatin suppress glucagon secretion, reducing hepatic glucose production.

Verified by multiple studies

which leads to

The combined reduction in hepatic glucose output and improved peripheral glucose disposal lowers fasting and postprandial blood glucose levels without increasing insulin secretion.

Verified by multiple studies

Evidence from Studies

Supporting (1)

Community contributions welcome

Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes.

Randomized Controlled Trial

Human

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals with Obesity and Pre-Diabetes.

Score: 89

DOI: 10.2337/db23-0356

Science Topic

Does sitagliptin improve insulin sensitivity and fasting glucose in obesity and prediabetes despite raising GLP-1 and GIP?

Supported

Sitagliptin & Insulin Sensitivity

We analyzed two assertions about sitagliptin in people with obesity and prediabetes, and both point to the same pattern: sitagliptin raises gut hormones like GLP-1 and GIP, but does not improve insulin sensitivity or lower fasting glucose [1][2]. This is different from liraglutide, which directly activates the same hormone receptors and does show changes in these measures [2]. The evidence we’ve reviewed suggests that simply increasing the levels of these hormones may not be enough to improve metabolic function in this group. Instead, directly stimulating their receptors — as liraglutide does — may be necessary to see benefits. We found no studies contradicting this pattern. What we’ve found so far leans toward the idea that the mechanism of action matters more than just raising hormone levels. Sitagliptin works by slowing the breakdown of GLP-1 and GIP, but this doesn’t appear to translate into better insulin response or lower fasting sugar in these individuals. This doesn’t mean the hormones aren’t important — it suggests that how they’re activated might be the key difference. For someone with prediabetes or obesity, this means that not all drugs that affect gut hormones work the same way, and what works for one may not work for another. The evidence doesn’t tell us why this happens, only that it does.

0 items of evidenceView full answer

Similar Assertions

In people with obesity and prediabetes, a drug called sitagliptin increases certain gut hormones but does not improve how the body responds to insulin or lower fasting blood sugar. This suggests that simply boosting these natural hormones is not enough—direct pharmacological activation of their receptors is needed for metabolic improvement.

95%

In people with obesity and prediabetes, the drug liraglutide lowers blood glucose levels after fasting and after meals within two weeks, even without weight loss. This effect is not seen with other approaches that increase GLP-1 naturally or reduce calories, suggesting liraglutide works through a distinct mechanism.

88%

In people with obesity and prediabetes, the drug liraglutide lowers blood glucose levels after eating and in the fasted state within two weeks, even without weight loss, and these effects are not seen with other approaches like sitagliptin or dieting alone.

86%

Blocking the GLP-1 receptor with exendin(9-39) eliminates the improvements in insulin sensitivity and blood glucose control that result from liraglutide treatment in people with obesity and prediabetes, indicating that these effects require GLP-1 receptor activity.

82%

Blocking the GLP-1 receptor with exendin(9-39) eliminates the improvements in insulin sensitivity and blood glucose control caused by liraglutide in people with obesity and prediabetes, indicating that these effects depend on activation of the GLP-1 receptor.

80%